Paroxetine

Generic Name: Paroxetine

Brand Names: Paxil, Pexeva

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀FNO_₃

CAS Number: 61869-08-7

Unique Ingredient Identifier: 41VRH5220H

Background: Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...

Indication: Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...

Associated Conditions: Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Associated Therapies: -

Clinical Trials

Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients

Phase 4

Terminated

Conditions: Major Depressive Disorder

Interventions: Drug: Paroxetine+Bupropion
Drug: Escitalopram+Mirtazapine
Drug: Paroxetine+Lamotrigine
Drug: Venlafaxine XR
Drug: Paroxetine+Lithium
Drug: Paroxetine + Venlafaxine XR
Drug: Escitalopram+Aripiprazole
Drug: paroxetine
Drug: Escitalopram

First Posted Date: 2009-06-24

Last Posted Date: 2015-09-02

Lead Sponsor: Ministry of Health & Welfare, Korea

Target Recruit Count: 692

Registration Number: NCT00926835

Locations: 🇰🇷
Clinical research center for depression, Seoul, Korea, Republic of

Lamotrigine Augmentation in Resistant Depression

Not Applicable

Completed

Conditions: Unipolar Depression

Interventions: Drug: placebo
Drug: lamotrigine
Drug: paroxetine

First Posted Date: 2009-05-13

Last Posted Date: 2009-05-13

Lead Sponsor: Louisiana State University Health Sciences Center in New Orleans

Target Recruit Count: 138

Registration Number: NCT00901407

Locations: 🇺🇸
LSUHSC- New Orleans, New Orleans, Louisiana, United States

Interaction Study of Timolol Eye Drops and Paroxetine Capsules

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Paroxetine
Drug: Placebo
Drug: timolol maleate

First Posted Date: 2009-04-09

Last Posted Date: 2010-01-28

Lead Sponsor: Santen Oy

Target Recruit Count: 12

Registration Number: NCT00879099

Locations: 🇫🇮
University of Helsinki, Department of Clinical Pharmacology, Helsinki, Biomedicum, Finland

BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder

Phase 3

Completed

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: Paroxetine

First Posted Date: 2009-02-09

Last Posted Date: 2014-03-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 52

Registration Number: NCT00839397

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

Phase 3

Terminated

Conditions: Anxiety Disorders

Interventions: Drug: No drug name provided by Sponsor; drug referenced as PD 0332334
Drug: Placebo
Drug: Paroxetine

First Posted Date: 2009-02-04

Last Posted Date: 2019-08-21

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 5

Registration Number: NCT00836069

Locations: 🇺🇸
Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences, Los Angeles, California, United States

Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

Phase 3

Completed

Conditions: Major Depressive Disorders

Interventions: Drug: amibegron (SR58611A)
Drug: placebo
Drug: paroxetine

First Posted Date: 2009-01-19

Last Posted Date: 2009-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 317

Registration Number: NCT00825058

Locations: 🇷🇸
Sanofi-Aventis Administrative Office, Belgrade, Serbia

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

Phase 3

Completed

Conditions: Major Depressive Disorders

Interventions: Drug: amibegron (SR58611A)
Drug: placebo
Drug: paroxetine

First Posted Date: 2009-01-19

Last Posted Date: 2009-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 306

Registration Number: NCT00825019

Locations: 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study

Phase 4

Conditions: Depression
Pain

First Posted Date: 2008-11-05

Last Posted Date: 2009-02-13

Lead Sponsor: University of Southern Denmark

Target Recruit Count: 12

Registration Number: NCT00785603

Treatment of Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain

Not Applicable

Conditions: Panic Disorder
Anxiety Disorder
Mental Disorder

Interventions: Behavioral: Brief cognitive-behavioral treatment for Panic Disorder
Behavioral: Cognitive-Behavior Therapy for Panic Disorder
Drug: paroxetine

First Posted Date: 2008-08-15

Last Posted Date: 2008-08-15

Lead Sponsor: Université du Québec a Montréal

Target Recruit Count: 204

Registration Number: NCT00736346

Locations: 🇨🇦
Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada
🇨🇦
Hôtel-Dieu de Lévis, Lévis, Quebec, Canada
🇨🇦
Institut de Cardiologie de Montréal (Montreal Heart Institute), Montréal, Quebec, Canada

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

Not Applicable

Completed

Conditions: Anxiety Disorders

Interventions: Drug: placebo
Drug: paroxetine
Drug: lorazepam

First Posted Date: 2008-07-15

Last Posted Date: 2008-10-03

Lead Sponsor: Pfizer

Target Recruit Count: 169

Registration Number: NCT00715039

Locations: 🇺🇸
Pfizer Investigational Site, Cincinnati, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy